Art

J-GLOBAL ID：201802273128617012   Reference number：18A1420647

Utility of eribulin therapy for patients with metastatic or recurrent breast cancer

転移・再発乳癌患者に対するエリブリン療法の有用性

Author (11)： KOIKE YOSHIKAZU (川崎医大 乳腺甲状腺外科学) ,  KUREBAYASHI JUN'ICHI (川崎医大 乳腺甲状腺外科学) ,  SUGAWARA SHIORI (川崎医大 乳腺甲状腺外科学) ,  KISHINO EMI (川崎医大 乳腺甲状腺外科学) ,  OGATA RYOHEI (川崎医大 乳腺甲状腺外科学) ,  SAITO WATARU (川崎医大 乳腺甲状腺外科学) ,  OTA YUSUKE (川崎医大 乳腺甲状腺外科学) ,  YAMASHITA TETSUMASA (川崎医大 乳腺甲状腺外科学) ,  NOMURA TSUNEHISA (川崎医大 乳腺甲状腺外科学) ,  YAMAMOTO YUTAKA (川崎医大 乳腺甲状腺外科学) ,  TANAKA KATSUHIRO (川崎医大 乳腺甲状腺外科学)
Material： 川崎医学会誌
Volume： 44  Issue： 1  Page： 71-78  Publication year： 2018 
JST Material Number： Z0386B  ISSN： 0386-5924  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： *antitumor drug ,...
Semi thesaurus term： overall survival ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1420647&from=J-GLOBAL&jstjournalNo=Z0386B") }}

JST classification (2)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (1)： Eribulin

Reference (12)：

• Jain S, Vahdat LT : Eribulin mesylate. Clin Cancer Res 17: 6615-6622, 2011
• Cortes J, O'Shaughnessy J, Loesch D, et al.: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377: 914-923, 2011
• Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y, Taguchi K, Sasaki Y, Takashima S: A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 23: 1441-1448, 2012
• Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J: Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6): 594-601, 2015
• Blum JL, Twelves CJ, Akerele S, et al.: Impact of the Number of Prior Chemotherapy Regimens on Overall Survival (OS) Among Subjects with Locally Recurrent or Metastatic Breast Cancer Treated with Eribulin Mesylate: Results from the phase III EMBRACE Study. Cancer Research70 (Suppl 2): P6-13-01, 2010

Terms in the title (5)： 再発乳癌 ,  患者 ,  エリブリン ,  療法 ,  有用性